Circulating tumor DNA to predict the risk of venous thromboembolism in locally advanced rectal cancer.
Cancer DNA in blood may predict dangerous blood clots in rectal cancer patients, revealing a new application for liquid biopsies.
Circulating tumor DNA levels were associated with VTE risk in locally advanced rectal cancer, suggesting ctDNA as a potential biomarker for thrombotic complications in this patient population. This dual role of ctDNA—in cancer monitoring and VTE prediction—represents an emerging application for liquid biopsy.
What the study was
- Study design
- retrospective_cohort
- Category
- early_cancer_detection
- Maturity
- Validated
Why it surfaced
Novel application of ctDNA liquid biopsy to VTE risk prediction in cancer patients—an emerging use case extending beyond tumor monitoring. Relevant to early cancer detection watchlist. Addresses a common and potentially preventable complication in cancer patients.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.